Introduction: Long noncoding RNAs (lncRNAs) have been implicated in the pathogenesis of allergic rhinitis (AR). The current investigation is focused on elucidating the functional impact of a specific lncRNA, FGD5 antisense RNA 1 (FGD5-AS1), on the development and progression of AR through its interaction with miR-223-3p. Methods: An experimental framework for AR was constructed in both cellular and animal models. Quantitative assessment of FGD5-AS1, miR-223-3p, and COX11 mRNA expression was conducted using real-time quantitative reverse transcription PCR. The expression of inflammatory factors, immunoglobulin E, LTC4, and ECP, was examined using ELISA. Apoptosis in human nasal epithelial cells was assessed by the flow cytometry method. The protein expression of COX11 was examined using Western blotting. Nasal mucosal function was further evaluated by hematoxylin and eosin staining. Furthermore, bioinformatics evaluations, dual-luciferase reporter assays, and a series of experimental procedures unveiled a putative competitive endogenous RNA regulatory mechanism. Results: We found the expression of lncRNA FGD5-AS1 was decreased in AR. In vitro lncRNA FGD5-AS1 attenuated the production of inflammatory cytokines in nasal epithelial cells. Furthermore, elevated FGD5-AS1 expression significantly alleviated AR symptoms by reducing nasal epithelial apoptosis and inflammation. MiR-223-3p was identified as a direct target of FGD5-AS1. Moreover, miRNA-223-3p directly downregulated the expression of COX11 mRNA. Subsequent experiments confirmed that FGD5-AS1 regulated AR through the miR-223-3p/COX11 axis, thereby inhibiting inflammation. Conclusion: The FGD5-AS1/miR-223-3p/COX11 axis plays a pivotal role in the pathogenesis of AR, suggesting that FGD5-AS1 could serve as a potential diagnostic biomarker and therapeutic target for AR.

Bousquet J, Anto JM, Bachert C, Baiardini I, Bosnic-Anticevich S, Walter Canonica G, et al. Allergic rhinitis. Nat Rev Dis Primers. 2020;6(1):95.
Bousquet PJ, Leynaert B, Neukirch F, Sunyer J, Janson CM, Anto J, et al. Geographical distribution of atopic rhinitis in the European community respiratory health survey I. Allergy. 2008;63(10):1301–9.
Vandenplas O, Vinnikov D, Blanc PD, Agache I, Bachert C, Bewick M, et al. Impact of rhinitis on work productivity: a systematic review. J Allergy Clin Immunol Pract. 2018;6(4):1274–86.e9.
Hoyte FCL, Nelson HS. Recent advances in allergic rhinitis. F1000Res. 2018;7:F1000 Faculty Rev-1333.
Yu QN, Guo YB, Li X, Li CL, Tan WP, Fan XL, et al. ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma. Allergy. 2018;73(9):1860–70.
Peng YQ, Qin ZL, Fang SB, Xu ZB, Zhang HY, Chen D, et al. Effects of myeloid and plasmacytoid dendritic cells on ILC2s in patients with allergic rhinitis. J Allergy Clin Immunol. 2020;145(3):855–67.e8.
Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152(6):1298–307.
Hadjicharalambous MR, Lindsay MA. Long non-coding RNAs and the innate immune response. Noncoding RNA. 2019;5(2):34.
Li M, Ma K, Feng Z, Wang J, Zhou X, Zhou L. Differential long non-coding RNA expression profiles in the peripheral blood and CD4(+)T cells of patients with active rheumatoid arthritis. Exp Ther Med. 2020;20(1):461–71.
Wells AC, Pobezinskaya EL, Pobezinsky LA. Non-coding RNAs in CD8 T cell biology. Mol Immunol. 2020;120:67–73.
Zhu X, Wang X, Wang Y, Zhao Y. Exosomal long non-coding RNA GAS5 suppresses Th1 differentiation and promotes Th2 differentiation via downregulating EZH2 and T-bet in allergic rhinitis. Mol Immunol. 2020;118:30–9.
Narozna B, Langwinski W, Szczepankiewicz A. Non-coding RNAs in pediatric airway diseases. Genes. 2017;8(12):348.
Yang Y, Dong MH, Hu HM, Min QH, Xiao L. LncRNA FGD5-AS1/miR-5590-3p axis facilitates the proliferation and metastasis of renal cell carcinoma through ERK/AKT signalling. Eur Rev Med Pharmacol Sci. 2020;24(17):8756–66.
Gandellini P, Doldi V, Zaffaroni N. microRNAs as players and signals in the metastatic cascade: implications for the development of novel anti-metastatic therapies. Semin Cancer Biol. 2017;44:132–40.
Wang S, Ling Y, Yao Y, Zheng G, Chen W. Luteolin inhibits respiratory syncytial virus replication by regulating the MiR-155/SOCS1/STAT1 signaling pathway. Virol J. 2020;17(1):187.
Ye C, Qi W, Dai S, Zou G, Liu W, Yu B, et al. microRNA-223 promotes autophagy to aggravate lung ischemia-reperfusion injury by inhibiting the expression of transcription factor HIF2α. Am J Physiol Lung Cel Mol Physiol. 2020;319(1):L1–10.
Specjalski K, Jassem E. MicroRNAs: potential biomarkers and targets of therapy in allergic diseases?Arch Immunol Ther Exp. 2019;67(4):213–23.
Zhou Y, Zhang T, Yan Y, You B, You Y, Zhang W, et al. MicroRNA-223-3p regulates allergic inflammation by targeting INPP4A. Braz J Otorhinolaryngol. 2021;87(5):591–600.
Wang WW, Zhu K, Yu HW, Pan YL. Interleukin-17A potentiates interleukin-13-induced eotaxin-3 production by human nasal epithelial cells from patients with allergic rhinitis. Int Forum Allergy Rhinol. 2019;9(11):1327–33.
Ouyang Y, Nakao A, Han D, Zhang L. Transforming growth factor-β1 promotes nasal mucosal mast cell chemotaxis in murine experimental allergic rhinitis. ORL J Otorhinolaryngol Relat Spec. 2012;74(3):117–23.
Nouri-Aria KT, O’Brien F, Noble W, Jabcobson MR, Rajakulasingam K, Durham SR. Cytokine expression during allergen-induced late nasal responses: IL-4 and IL-5 mRNA is expressed early (at 6 h) predominantly by eosinophils. Clin Exp Allergy. 2000;30(12):1709–16.
Lei Z, Feng G, Wang Z, Ning Z. Noncoding RNAs and virus and treatment in allergic rhinitis. Evid Based Complement Alternat Med. 2022;2022:1979447.
Zhang H, Zhu X, Liu X, Wang Y, Liu Y. Long non-coding RNA FOXD3-AS1 regulates the expression and secretion of IL-25 in nasal epithelial cells to inhibit Th2 type immunoreaction in allergic rhinitis. Mol Cell Biochem. 2020;473(1–2):239–46.
Sayad A, Mirzajani S, Gholami L, Razzaghi P, Ghafouri-Fard S, Taheri M. Emerging role of long non-coding RNAs in the pathogenesis of periodontitis. Biomed Pharmacother. 2020;129:110362.
Hu H, Wu J, Li D, Zhou J, Yu H, Ma L. Knockdown of lncRNA MALAT1 attenuates acute myocardial infarction through miR-320-Pten axis. Biomed Pharmacother. 2018;106:738–46.
Fan Y, Li H, Yu Z, Dong W, Cui X, Ma J, et al. Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1. Biosci Rep. 2020;40(1):BSR20193309.
Liu Z, Liu J, Wei Y, Xu J, Wang Z, Wang P, et al. LncRNA MALAT1 prevents the protective effects of miR-125b-5p against acute myocardial infarction through positive regulation of NLRC5. Exp Ther Med. 2020;19(2):990–8.
Fang XL, Shi SG. lncRNA FGD5-AS1 acts as a ceRNA to regulate lipopolysaccharide-induced injury via the miR-223-3p-3p/GAS5 axis in cardiomyocytes. Hum Exp Toxicoly. 2022;41:9603271221138969.
Yang F, Xu Y, Liu C, Ma C, Zou S, Xu X, et al. NF-kappa B/miR-223-3p/ARID1A axis is involved in Helicobacter pylori CagA-induced gastric carcinogenesis and progression. Cell Death Dis. 2018;9(1):12.
Ji Q, Xu X, Song Q, Xu Y, Tai Y, Goodman SB, et al. miR-223-3p inhibits human osteosarcoma metastasis and progression by directly targeting CDH6. Mol Ther. 2018;26(5):1299–312.
Wan L, Yuan X, Liu M, Xue B. miRNA-223-3p regulates NLRP3 to promote apoptosis and inhibit proliferation of hep3B cells. Exp Ther Med. 2018;15(3):2429–35.
Radin I, Mansilla N, Rödel G, Steinebrunner I. The arabidopsis COX11 homolog is essential for cytochrome c oxidase activity. Front Plant Sci. 2015;6:1091.
Benson M, Strannegård IL, Strannegård O, Wennergren G. Topical steroid treatment of allergic rhinitis decreases nasal fluid T(H)2 cytokines, eosinophils, eosinophil cationic protein, and IgE but has no significant effect on IFN-gamma, IL-1 beta,TNF-alpha, or neutrophils. J Allergy Clin Immunol. 2000;106(2):307–12.
Settipane RA, Schwindt C. Chapter 15: allergic rhinitis. Am J Rhinol Allergy. 2013;27(Suppl 1):52–5.
Takeuchi H, Konnai S, Maekawa N, Takagi S, Ohta H, Sasaki N, et al. Canine transforming growth factor-beta receptor 2-Ig: a potential candidate biologic for melanoma treatment that reverses transforming growth factor-beta 1 immunosuppression. Front Vet Sci. 2021;8:656715.
You do not currently have access to this content.